Table I Demographics and clinical characteristics and LAMC2 and CA19.9 levels according to the cohorts. PDAC, pancreatic ductal adenocarcinoma; CP, Chronic pancreatitis; PD, pancreatic ductal, S.E., standard error, x; data not available
VariableUS cohortGerman cohortPDAC-inoperableJapanese cohort
ControlBenignPDAC-stage IIBPDAC-stage IVControlBenignPDAC-operableControlBenignPDAC
Number of subjects2015252550505050505050
Age (years Mean ± S.E.)59.8 ± 4.3955.6 ± 4.7464.4 ± 1.9362.1 ± 1.9258.3 ± 2.449.8 ± 1.467.3 ± 1.163.7 ± 1.464.1 ± 1.160 ± 1.263.4 ± 1.2
Sex (M/F)
Male5818153131303126xx
Female1577101919201924xx
Race
White20142423xxxxxxx
Othersx112xxxxxxx
Risk factors
Smokers7111810xxxxxxx
Diabetes4784
Chronic pancreatitisx14xxx50xxx7x
Pancreatic cystx1xxxxxxx35x
PD dilationxxxxxxxxx8x
Serological concentrations
LAMC2-ng/ml (Mean ± S.E.)130.6 ± 25.4244.7 ± 63.2489.6 ± 69.7510 ± 62179.2 ± 32.7261.2 ± 36.5487.7 ± 51.3394.1 ± 45.687 ± 6.9140 ± 20382.2 ± 44
CA19.9-U/ml (Mean ± S.E.)12.8 ± 2.861.1 ± 15.7804.15 ± 415.34167.9 ± 879.57.6 ± 0.927.3 ± 12.7332.3 ± 100872.3 ± 290.521.6 ± 4.6101.2 ± 56.51699.7 ± 437.9